PSA Monitoring After RARP vs Radiotherapy for Biochemical Recurrence
After radical prostatectomy (including RARP), biochemical recurrence is defined as PSA ≥0.2 ng/mL confirmed by a second measurement ≥0.2 ng/mL, while after radiotherapy, recurrence is defined as PSA rise ≥2.0 ng/mL above nadir (Phoenix criteria). 1, 2
Post-RARP PSA Monitoring
The standard approach requires periodic PSA determinations with a washout period of at least 6 weeks before obtaining the first postoperative PSA value. 1, 3
Biochemical Recurrence Definition
- Primary threshold: PSA ≥0.2 ng/mL followed by confirmatory PSA ≥0.2 ng/mL 1, 2
- Alternative threshold of 0.4 ng/mL may better predict metastatic relapse risk, though 0.2 ng/mL remains the standard for reporting outcomes 1
- Any detectable PSA should be repeated for confirmation to eliminate laboratory error 3
Monitoring Schedule
While the EAU guidelines traditionally recommend biannual PSA testing for 3 years followed by annual testing 4, recent evidence supports risk-adapted monitoring schedules that reduce unnecessary testing without compromising detection rates 4:
- Low-risk patients: 4 consultations over 5 years
- Intermediate-risk patients: 8 consultations over 5 years
- High-risk patients: 10 consultations over 5 years
This risk-adapted approach reduces consultations by 18% compared to standard EAU schedules with only 3% delayed BCR detection 4.
Critical Timing Considerations
Most biochemical recurrences with PSA >0.4 ng/mL occur within the first year postoperatively 5. Therefore, more frequent monitoring during the first 6-12 months is essential, particularly for high-risk patients who may benefit from early salvage therapy at lower PSA thresholds (≥0.03 ng/mL) 6.
Post-Radiotherapy PSA Monitoring
Following radiotherapy, PSA should fall to a low level and remain stable, with recurrence defined by the Phoenix criteria: PSA rise ≥2.0 ng/mL above nadir. 1
Key Differences from Post-RARP Monitoring
- PSA values <0.2 ng/mL are uncommon after external beam radiotherapy since it does not ablate all prostate tissue 1
- "Benign bounces" (intermittent PSA rises) are characteristic after brachytherapy, with median PSA levels around 0.1 ng/mL 1
- PSA levels continue to decline for more than 5 years after brachytherapy 1
- A PSA level <0.7 ng/mL at 5 years is reasonable for brachytherapy 1
Biochemical Recurrence Definition
- Phoenix criteria: PSA rise ≥2.0 ng/mL above nadir, regardless of androgen deprivation 1
- Alternative: 3 consecutive PSA rises 1
- Time of failure is NOT backdated to the first PSA rise 1
Common Pitfalls and Caveats
Post-RARP Monitoring
Persistent PSA: 5-20% of men have detectable PSA (≥0.1 ng/mL) within 4-8 weeks after surgery 7. This carries poor prognosis with 74% experiencing further progression 7. These patients may benefit from early aggressive multimodality treatment, though prospective RCT data are lacking 7.
PSA threshold selection: Lower thresholds (0.2 ng/mL) increase sensitivity for detecting recurrence, while higher thresholds (0.4 ng/mL) improve specificity 3. The 0.2 ng/mL threshold remains standard for clinical practice 2.
Salvage therapy timing: Effectiveness of salvage radiotherapy is greatest when administered at lower PSA levels 8. However, 8.8% of patients with biochemical recurrence may have stable detectable PSA for ≥10 years without clinical failure 8.
Post-Radiotherapy Monitoring
Benign bounces: Intermittent PSA rises after brachytherapy do not necessarily indicate recurrence 1. A consistently rising PSA usually, though not always, indicates cancer recurrence 1.
Nadir considerations: PSA nadir is a critical risk factor but is not incorporated into the Phoenix definition itself 3.
Risk stratification limitations: Current EAU BCR risk criteria show moderate discrimination (C-index 0.69 for RT) 9. Notably, low-risk BCR after RT showed substantial 10-year cancer-specific mortality (18.4%), exceeding high-risk post-RP mortality (12%) 9, suggesting current criteria inadequately stratify risk after radiotherapy.
Clinical Implementation
Regular PSA monitoring should be offered to all patients after definitive treatment to enable early administration of salvage therapies 1. The decision to initiate salvage therapy should incorporate pathology findings, risk factors, family history, and patient preferences, particularly in the era of ultrasensitive PSA assays where confirmed rising PSA may trigger salvage therapy in high-risk patients 8.
For post-RARP patients, surveillance with selective imaging use is appropriate 1, with restaging evaluation considered when PSA recurrence is detected, though imaging yield is extremely low when PSA <10 ng/mL 8.